Puma Biotechnology Inc. (NYSE: PBYI) is looking forward to proceeding with the regulatory filing for neratinib for the extended adjuvant treatment of breast cancer in the first quarter of 2016. The company expects to have a New Drug Approval in this quarter for its PB272. This also represents the first trial with a HER2 targeted agent that has shown a statistically significant benefit in the extended adjuvant setting, which Puma believes will provide a meaningful point of differentiation for neratinib in the treatment of HER2 positive breast cancer. Puma shares were last trading at $78.40. The consensus price target is $134.25. The 52-week trading range is $56.11 to $252.92.